SARS‐CoV‐2 At diagnosis of acute lymphoblastic leukemia—Case series. To worry about COVID or leukemia? A developing country's perspective

Sneha, Latha M.; Tatapudi, Vahnita; Scott, Julius Xavier; Suman, F. R.; Gayathri, S.; Jayaraman, Dhaarani

doi:10.1002/pbc.29124

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is particularly true among patients with acute lymphoblastic leukemia (ALL). However, given the rarity of this disease in adulthood, information is limited and based, so far, mainly on case reports, [4][5][6] with only two larger series having been published. 7,8 In order to define the clinico-biological features of the COVID-19-infected ALL population, and their ALL management and ALL outcome, as well as COVID-19-related variables, e.g.…”

mentioning

confidence: 99%

COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report

Chiaretti¹,

Bonifacio

Agrippino³

et al. 2022

haematol

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report

Chiaretti¹,

Bonifacio

Agrippino³

et al. 2022

haematol

View full text Add to dashboard Cite

show abstract

“…The detailed characteristics of the included studies are shown in Table 1. There were 83 case report (3, 4, 17, 22, 25, 28-30, 33, 34, 36, 57, 58, 61, 63-66, 68, 71-73, 76, 77, 79-84, 86-90, 94, 95, 97-102, 105, 106, 109, 111, 112, 114, 115, 117, 118, 120-122, 124-127, 132-142, 145, 147-149, 152, 154, 156-158, 160, 164-166), 54 cohort (7, 8, 12-16, 18, 20, 21, 24, 26, 31, 32, 35, 37-40, 59, 62, 67, 69, 70, 74, 75, 91-93, 96, 103, 104, 107, 108, 113, 116, 123, 129-131, 144, 150, 155, 159, 161, 167-172, 174-176), and 18 case-series (19,23,27,60,78,85,110,119,128,143,146,151,153,162,163,173,177,178) studies. These studies were conducted in United States (n = 27), India (n = 17), China (n = 10), Turkey (n = 9), Italy (n = 9), Iran (n = 8), Mexico (n = 8), United Kingdom (n = 6), Spain (n = 6), Poland (n = 5), Brazil (n = 5), France (n = 4), Peru (n = 3), Switzerland (n = 3), Greece (n = 3), Pakistan (n = 2), Saudi Arabia (n = 2), Russia (n = 2), Austria (n = 2), Germany (n = 2), Jordan (n = 2), Algeria (n = 1), The Netherlands (n = 1), Kuwait (n = 1), Egypt (n = 3), Oman (n = 1), Romania (n = 1), Colombia (n = 1), Israel (n = 1), Taiwan (n = 1), Canada (n = 1), Indonesia (n = 1), Argentina (n = 1), Tunisia (n = 1), Palestine (n = 1), Japan (n = 1) and Sweden (n = 1).…”

Section: Study Characteristics and Qualitymentioning

confidence: 99%

Blood cancer in children infected with COVID-19: A comprehensive systematic review

Alhumaid,

Noaim,

Almuslim

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Blood cancer is the most common type of cancer and the leading cause of death by disease past infancy among children. Children with blood cancer are vulnerable population to viral infections such as coronavirus disease 2019 (COVID-19). Objectives: To estimate the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in blood cancer children and analyse the demographic parameters, clinical characteristics and treatment outcomes in blood cancer children with COVID-19 illness. Methods: For this systematic review, we searched ProQuest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guideline for studies on the development of COVID-19 in children with blood cancer, published from December 1, 2019 to April 30, 2023, with English language restriction. Results: Of the 3077 papers that were identified, 155 articles were included in the systematic review (83 case report, 54 cohort and 18 case-series studies). Studies involving 1289 blood cancer children with confirmed COVID-19 were analysed. Leukaemias (1141 cases) were the most frequent types of blood cancer observed in children who developed COVID-19, followed by non-Hodgkin’s lymphomas (59 cases), Hodgkin’s lymphomas (36 cases), Langerhans cell histiocytosis (7 cases), myelodysplastic syndrome (7 cases) and myeloid neoplasm (1 case). Among all 1289 blood cancer paediatric cases who transmitted SARS-CoV-2, some children were documented to be admitted to the intensive care unit (ICU) (n = 175, 13.6%), intubated and placed on mechanical ventilation (n = 111, 8.6%), suffered acute respiratory distress syndrome (n = 144, 11.2%) or died (n = 111, 8.6%). Overall, COVID-19 in children with different types of blood cancer resulted in no or low severity of disease in more than 78.6% of all included cases (COVID-19 severity: asymptomatic = 239, mild = 603, or moderate = 171). Treatment for COVID-19 was not necessary in a high number of blood cancer children (n = 94, 7.3%). Fatality in blood cancer children with COVID-19 was reported in any of the included blood cancer categories for leukaemias (n = 99, 8.7%), non-Hodgkin’s lymphomas (n = 7, 11.9%), Hodgkin’s lymphomas (n = 2, 5.5%), myelodysplastic syndrome (n = 1, 14.3%) or myeloid neoplasm (n = 1, 100%). Fatality rate in blood cancer children infected with SARS-CoV-2 was the highest in patients with Hispanic ethnicity (n = 44/111, 39.6%) and COVID-19–related fatality was highest in male patients (76.5% of deceased patients). Most studies reported to alter the intensity and regimen of anticancer treatment in blood cancer children during course of SARS-CoV-2 infection, however, many studies have reported to successfully treat COVID-19 without any changes to the anticancer treatment. Conclusion: Globally, leukaemias were the most prevalent and myeloid neoplasms were the least prevalent blood cancer types in children who developed SARS-CoV-2 infection. Children with blood cancer tend to have milder COVID-19 symptoms and are less likely to be hospitalized and have better prognosis when compared to adults. Continuation of anticancer treatment in individual paediatric blood cancer patients with COVID-19 seems to be possible.

show abstract

SARS‐CoV‐2 At diagnosis of acute lymphoblastic leukemia—Case series. To worry about COVID or leukemia? A developing country's perspective

Cited by 2 publications

References 6 publications

COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report

COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report

Blood cancer in children infected with COVID-19: A comprehensive systematic review

Contact Info

Product

Resources

About